Sarcopenia - Pipeline Insight, 2025
Description
DelveInsight’s, “Sarcopenia - Pipeline Insight, 2025” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Sarcopenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Sarcopenia: Overview
Sarcopenia is a progressive, age-related condition characterized by the loss of skeletal muscle mass, strength, and function. It primarily affects older adults and is associated with an increased risk of falls, frailty, reduced mobility, and overall decline in quality of life. While aging is the primary driver, other contributing factors include chronic diseases, inflammation, hormonal changes, poor nutrition, and physical inactivity. Sarcopenia is now recognized as a distinct disease by the World Health Organization (WHO) and is increasingly gaining attention in clinical research due to its significant impact on aging populations.
The pathophysiology of sarcopenia involves a combination of muscle protein imbalance, mitochondrial dysfunction, neuromuscular degradation, and increased inflammatory cytokines. A decline in anabolic hormones, such as testosterone and growth hormone, coupled with an increase in catabolic processes, accelerates muscle degradation. Additionally, insulin resistance and chronic low-grade inflammation contribute to muscle atrophy and impaired regeneration. The loss of type II muscle fibers, which are responsible for quick and powerful movements, further exacerbates functional impairment.
Diagnosis of sarcopenia typically relies on criteria that assess muscle mass, strength, and physical performance. Common diagnostic tools include dual-energy X-ray absorptiometry (DXA) or bioelectrical impedance analysis (BIA) for muscle mass evaluation, handgrip strength tests for muscle strength, and gait speed measurements for functional assessment. The European Working Group on Sarcopenia in Older People (EWGSOP) and other international bodies have developed guidelines to standardize diagnosis and classification, which helps in identifying individuals at risk and guiding clinical management.
Treatment and prevention strategies for sarcopenia focus on resistance exercise, adequate protein intake, and potential pharmacological interventions. Strength training remains the most effective intervention for improving muscle mass and function, while ensuring sufficient dietary protein—especially leucine-rich sources—supports muscle synthesis. Emerging therapeutic approaches include myostatin inhibitors, selective androgen receptor modulators (SARMs), and anti-inflammatory agents, though none have yet been widely approved for clinical use. As the global population ages, addressing sarcopenia will be critical for maintaining independence and reducing the burden of age-related disability.
""Sarcopenia- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sarcopenia pipeline landscape is provided which includes the disease overview and Sarcopenia treatment guidelines. The assessment part of the report embraces, in depth Sarcopenia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sarcopenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Sarcopenia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sarcopenia Emerging Drugs
In humans and rodents, 15-PGDH gene expression is elevated in muscle coincident with the onset of age-induced muscle weakness. PGE2, a lipid signaling molecule with multiple beneficial effects on the motor unit, including enhanced muscle quality and improved function of the neuromuscular junction, is reduced in skeletal muscle of aged mice due to increased activity of 15-PGDH. Inhibiting 15-PGDH in aged muscle may be a strategy to increase physiologic levels of PGE2 to improve muscle quality and function. Currently, the drug is in the Phase I stage of its development for the treatment of Sacropenia.
Further product details are provided in the report……..
Sarcopenia: Therapeutic Assessment
This segment of the report provides insights about the different Sarcopenia drugs segregated based on following parameters that define the scope of the report, such as:
Sarcopenia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sarcopenia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sarcopenia drugs.
Sarcopenia Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Sarcopenia: Overview
Sarcopenia is a progressive, age-related condition characterized by the loss of skeletal muscle mass, strength, and function. It primarily affects older adults and is associated with an increased risk of falls, frailty, reduced mobility, and overall decline in quality of life. While aging is the primary driver, other contributing factors include chronic diseases, inflammation, hormonal changes, poor nutrition, and physical inactivity. Sarcopenia is now recognized as a distinct disease by the World Health Organization (WHO) and is increasingly gaining attention in clinical research due to its significant impact on aging populations.
The pathophysiology of sarcopenia involves a combination of muscle protein imbalance, mitochondrial dysfunction, neuromuscular degradation, and increased inflammatory cytokines. A decline in anabolic hormones, such as testosterone and growth hormone, coupled with an increase in catabolic processes, accelerates muscle degradation. Additionally, insulin resistance and chronic low-grade inflammation contribute to muscle atrophy and impaired regeneration. The loss of type II muscle fibers, which are responsible for quick and powerful movements, further exacerbates functional impairment.
Diagnosis of sarcopenia typically relies on criteria that assess muscle mass, strength, and physical performance. Common diagnostic tools include dual-energy X-ray absorptiometry (DXA) or bioelectrical impedance analysis (BIA) for muscle mass evaluation, handgrip strength tests for muscle strength, and gait speed measurements for functional assessment. The European Working Group on Sarcopenia in Older People (EWGSOP) and other international bodies have developed guidelines to standardize diagnosis and classification, which helps in identifying individuals at risk and guiding clinical management.
Treatment and prevention strategies for sarcopenia focus on resistance exercise, adequate protein intake, and potential pharmacological interventions. Strength training remains the most effective intervention for improving muscle mass and function, while ensuring sufficient dietary protein—especially leucine-rich sources—supports muscle synthesis. Emerging therapeutic approaches include myostatin inhibitors, selective androgen receptor modulators (SARMs), and anti-inflammatory agents, though none have yet been widely approved for clinical use. As the global population ages, addressing sarcopenia will be critical for maintaining independence and reducing the burden of age-related disability.
""Sarcopenia- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sarcopenia pipeline landscape is provided which includes the disease overview and Sarcopenia treatment guidelines. The assessment part of the report embraces, in depth Sarcopenia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sarcopenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Sarcopenia R&D. The therapies under development are focused on novel approaches to treat/improve Sarcopenia.
This segment of the Sarcopenia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sarcopenia Emerging Drugs
- BIO101: Biophytis
- MF-300: Epirium Bio
In humans and rodents, 15-PGDH gene expression is elevated in muscle coincident with the onset of age-induced muscle weakness. PGE2, a lipid signaling molecule with multiple beneficial effects on the motor unit, including enhanced muscle quality and improved function of the neuromuscular junction, is reduced in skeletal muscle of aged mice due to increased activity of 15-PGDH. Inhibiting 15-PGDH in aged muscle may be a strategy to increase physiologic levels of PGE2 to improve muscle quality and function. Currently, the drug is in the Phase I stage of its development for the treatment of Sacropenia.
- TRN005: Turn Biotechnologies
Further product details are provided in the report……..
Sarcopenia: Therapeutic Assessment
This segment of the report provides insights about the different Sarcopenia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Sarcopenia
- There are approx. 18+ key companies which are developing the therapies for Sarcopenia. The companies which have their Sarcopenia drug candidates in the most advanced stage, i.e. phase II include, Biophytis.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Sarcopenia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sarcopenia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sarcopenia drugs.
Sarcopenia Report Insights
- Sarcopenia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Sarcopenia drugs?
- How many Sarcopenia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sarcopenia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sarcopenia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Sarcopenia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Biophytis
- Epirium Bio
- Turn Biotechnologies
- Immunis
- Oncocross
- BPGbio, Inc.
- BIO101
- MF-300
- TRN005
- IMM01-STEM
- OC514
- BPM31510
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Sarcopenia: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Sarcopenia– DelveInsight’s Analytical Perspective
- Mid Stage Products (Phase II)
- Comparative Analysis
- BIO101: Biophytis
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- MF-300: Epirium Bio
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Comparative Analysis
- TRN005: Turn Biotechnologies
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Sarcopenia Key Companies
- Sarcopenia Key Products
- Sarcopenia- Unmet Needs
- Sarcopenia- Market Drivers and Barriers
- Sarcopenia- Future Perspectives and Conclusion
- Sarcopenia Analyst Views
- Sarcopenia Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
